Get the PDF Here –
Disease Overview: Waldenström macroglobulinemia (WM) is a lymphoplasmacytic lymphoma with immunoglobulin M (IgM) monoclonal protein. Clinical features include anemia, thrombocytopenia, hepatosplenomegaly, lymphadenopathy, and rarely hyperviscosity.
Diagnosis: Presence… Continue reading
The National Comprehensive Cancer Network has provided a new Waldenstrom’s Macroglobuliemia Guidelines document. These are the guidelines that are followed by Medicare and many other insurance companies.
It is a good development in the education of Waldenstrom’s Macroglobulinemia.
NCCN_2017_WM Guidelines for Patients
We would like to thank all of our presenters from the 2016 WMFC Educational Forum held in Toronto on November 12, 2016.
We have made some of the presentations available for viewing online – click the link below.
Dr. Christine… Continue reading
The WMFC would like to extend a big thank you to Paul Kitchen for sponsoring the 2016 Educational Forum.
Paul Kitchen – Bio
Paul was one of the longest serving Heads of independent schools in Canada, retiring last June… Continue reading
Contributing Member – Ron Ternoway
Ron Ternoway has shared his experience with WM in “Trials of a Wally”. We thought we would share with the WMFC community!
READ MORE HERE
Meletios Dimopoulos, MD
Improved understanding of Waldenström’s macroglobulinemia (WM) and expanded treatment options have made individualized treatment based on clinical indications a feasible strategy, Meletios Dimopoulos, MD, said at the 2016 Society of Hematologic Oncology annual… Continue reading
Treatment recommendations from the Eighth International Workshop on Waldenström’s Macroglobulinemia
Please find below a list of clinical trials available. Please click on Clinical Trial Number to link to more information.
Canadian WM Clinical Trials Sept. 2016